The RNAi therapeutics market is anticipated to grow at an annualized rate of more than 45%, till 203

Roots Analysis has announced the addition of “RNAi Therapeutics Market (2nd Edition), 2019-2030” report to its list of offerings.

Significant advancements in the developmental pipeline across various oncological disorders, infectious diseases and genetic disorders have amplified the interest of various pharmaceutical establishments and have inspired research groups across the world, to focus their efforts on the development of RNAi therapeutics. Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.

To order this 350+ page report, which features 130+ figures and 190+ tables, please visit this – https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html

Key Market Insights

Over 170 RNAi therapeutics are currently under development
Nearly 30% of pipeline drugs are in the clinical phase, while the rest are either in the preclinical / discovery stage. The majority of pipeline drug candidates are delivered using siRNA conjugated delivery technology platform to mitigate targeted delivery to organ / cell.

More than 70% of ongoing clinical trials are being conducted in North America and Europe
In total, we came across over 100 clinical trials that have been / are being conducted across the globe. It is worth noting that around 40% of these trials were observed to be phase II studies. Further, 75% of the active clinical trials being conducted in this domain are evaluating siRNAs.

Over 36,000 patents were filed / granted related to RNAi therapeutics since 2014
Majority of these were patent applications (59%), followed by granted patents (40%).

Contact:

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com

Leave a Reply

Your email address will not be published. Required fields are marked *